Fig. 3From: Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritisBreak-even dose and frequency of infliximab versus stable-dose intravenous golimumab, across a range of discounting assumed for biosimilar infliximab. Note: positive numbers reflect greater costs for infliximab, and negative numbers reflect a cost savings for use of infliximab, compared to golimumab IVBack to article page